Mikhail N. Kosiborod MD, FACC, FAHA

Dr. Mikhail Kosiborod's research has a strong focus on the intersection of diabetes and cardiovascular disease. He is Vice President of Research at Saint Luke’s Health System; Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid-America Heart Institute; and Professor of Medicine at the University of Missouri-Kansas City. He is an internationally recognized expert in diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes, as well as quality of care and outcomes. He received training in clinical research, epidemiology, and health policy through the Robert Wood Johnson Clinical Scholars Program, as well as clinical training in cardiovascular medicine at Yale University School of Medicine.

As a practicing clinician and researcher, Dr. Kosiborod seeks to establish a practical system of implementing the adoption of new treatments that have been proven to be life-saving into practice in a more timely manner. He continues to be involved in the leadership of numerous clinical trials and multi-center registries, and serves as the Principal Investigator of investigator-initiated, multi-center trials in diabetes and cardiovascular disease, most recently of SGLT2 inhibition.